All In Biotech

Drug Trial Radar · NCT02944487

A Study to Assess the Safety and Pharmacokinetics of Lucerastat (OGT 923) in Healthy Subjects

A Randomised, Double-blind, Placebo-controlled Ascending Dose Tolerance Study of OGT 923 in Healthy Male Volunteers

Last checked: Nov 19, 2026Latest source record: May 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

39

Actual

Start

Oct 2002

Primary completion

Dec 2002

Study completion Dec 2002

Sponsor

Lead sponsor
Idorsia Pharmaceuticals Ltd.Industry
Sponsor type
Industry
First posted
Oct 26, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Other
Who can join
Male only, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The objectives of this study were to evaluate the safety and tolerability of lucerastat, and to determine its pharmacokinetic profile as single oral doses at different strengths.

Conditions

  • Healthy Subjects

Interventions

  • LucerastatDrug

    Hard gelatin capsule for oral administration containing lucerastat

  • PlaceboDrug

    Matching placebo capsules

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with Adverse Events (AEs)Time frame: From baseline up to 7 days post-administration
  2. Maximum plasma concentration (Cmax) of lucerastat after single ascending doses of lucerastatTime frame: PK Blood samples were collected at pre-dose and at scheduled time points up to 24 hours post administration
  3. Maximum plasma concentration (Cmax) of lucerastat after two daily doses of lucerastatTime frame: PK Blood samples were collected at pre-dose and at scheduled time points up to 48 hours after the first administration
  4. Time to reach Cmax (tmax) of lucerastat after single ascending doses of lucerastatTime frame: PK Blood samples were collected at pre-dose and at scheduled time points up to 24 hours post administration
  5. Time to reach Cmax (tmax) of lucerastat after two daily doses of lucerastatTime frame: PK Blood samples were collected at pre-dose and at scheduled time points up to 48 hours after the first administration
  6. Area under the plasma concentration-time curves (AUC) of lucerastat after single ascending doses of lucerastatTime frame: PK Blood samples were collected at pre-dose and at scheduled time points up to 24 hours post administration
  7. Area under the plasma concentration-time curves (AUC) of lucerastat after two daily doses of lucerastatTime frame: PK Blood samples were collected at pre-dose and at scheduled time points up to 48 hours after the first administration
  8. Terminal elimination half-life (t1/2) of lucerastat after single ascending doses of lucerastatTime frame: PK Blood samples were collected at pre-dose and at scheduled time points up to 24 hours post administration
  9. Terminal elimination half-life (t1/2) of lucerastat after two daily doses of lucerastatTime frame: PK Blood samples were collected at pre-dose and at scheduled time points up to 48 hours after the first administration

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Investigator Site

    Tranent, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.